Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.51 |
| ▸ | FHIT | P49789 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495320 | 0.89 | KMT2A (0.63) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL11945535 | 0.86 | ALDH1A1 (0.60) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL28748453 | 0.85 | KMT2A (0.50) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL25078375 | 0.84 | CYP2C9 (0.68) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL388564 | 0.84 | ALDH1A1 (0.76) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL924805 | 0.84 | ALDH1A1 (0.62) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL28748494 | 0.83 | KMT2A (0.48) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL25078677 | 0.82 | ALDH1A1 (0.61) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL25077913 | 0.82 | RIPK1 (0.48) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL28748478 | 0.82 | KMT2A (0.50) | KMT2ACYP2C19CYP1A2CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| US-10479771-B2 | Pyridazinone and pyridone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2019-11-19 | — | — | US | disclosed |
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2018-02-01 | — | — | US | disclosed |
| US-9815795-B2 | Pyridazinone and pyridone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2017-11-14 | — | — | US | disclosed |
| EP-2683711-B1 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORP (FI) | 2017-02-01 | — | — | EP | disclosed |
| US-20160244414-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2016-08-25 | — | — | US | disclosed |
| US-9371290-B2 | Pyridazinone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2016-06-21 | — | — | US | disclosed |
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20140024648-A1 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2014-01-23 | — | — | US | disclosed |
| EP-2683711-A1 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS | Biotie Therapies Corp. (FI) | 2014-01-15 | — | — | EP | disclosed |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | KMT2A 2017/4885CYP2C19 234/4885CYP1A2 549/4885 |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | NRAS, BRAF, MAPK9 | KMT2A 2066/4885CYP2C19 226/4885CYP1A2 574/4885 |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | KMT2A 2233/4885CYP2C19 235/4885CYP1A2 604/4885 |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | KMT2A 2321/4885CYP2C19 181/4885CYP1A2 610/4885 |
| US-20160244414-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | KMT2A 3561/4885CYP2C19 11/4885CYP1A2 14/4885 |
| US-20140024648-A1 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | KMT2A 3560/4885CYP2C19 23/4885CYP1A2 20/4885 |
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | KMT2A 3561/4885CYP2C19 11/4885CYP1A2 14/4885 |
| US-10479771-B2 | Pyridazinone and pyridone compounds | XDH, PNPO, PDXK | KMT2A 3561/4885CYP2C19 11/4885CYP1A2 14/4885 |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, MAPK9 | KMT2A 2188/4885CYP2C19 207/4885CYP1A2 644/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | KMT2A 2192/4885CYP2C19 203/4885CYP1A2 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.